Fairly good revenue though, gives me confidence that MSB will be very successful.
The poor growth could also be contributed to bad efficacy. Long-term followers on HC may remember this announcement, even more significant to our indication.
https://www.businesswire.com/news/home/20200102005480/en/Incyte-Announces-Results-of-Phase-3-Study-of-Itacitinib-in-Patients-with-Treatment-Na%C3%AFve-Acute-Graft-Versus-Host-Disease
Not what they would have hoped for. Gold standard failure. Look at the response, not that bad yet it failed.
Indeed this data is better than the approved drug.
How can that be. ????
Cell Therapy News/Articles, page-14082
-
- There are more pages in this discussion • 3,946 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.06 |
Change
0.030(2.91%) |
Mkt cap ! $1.210B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $5.796M | 5.430M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15990 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 48632 | 3 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |